Prognostic Risk Factors of Carbapenem-Resistant Gram-Negative Bacteria Bloodstream Infection in Immunosuppressed Patients: A 7-Year Retrospective Cohort Study
Yulian Gao,Hongxia Lin,Yumin Xu,Yijin Yao,Dake Shi,Junjie Li,Haixing Zhu,Hanssa Dwarka Summah,Lei Ni,Yun Feng
DOI: https://doi.org/10.2147/IDR.S386342
2022-11-03
Infection and Drug Resistance
Abstract:Yulian Gao, 1, &ast Hongxia Lin, 1, &ast Yumin Xu, 2, &ast Yijin Yao, 1, &ast Dake Shi, 1 Junjie Li, 1 Haixing Zhu, 1 Hanssa Dwarka Summah, 3 Lei Ni, 1 Yun Feng 1 1 Department of Respiratory and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 2 Department of Hospital Infection Management, Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 3 Department of Respiratory, Poudre D'Or Chest Hospital, Rivière du Rempart, Mauritius &astThese authors contributed equally to this work Correspondence: Yun Feng; Lei Ni, Email ; Purpose: Carbapenem-resistant Gram-negative bacteria bloodstream infection (CRGNB-BSI) has gradually become a major threat worldwide due to its treatment difficulty and high mortality. This study aimed to determine the risk factors for CRGNB-BSI in immunosuppressed patients. Patients and Methods: A total of 427 immunosuppressed patients with CRGNB-BSI were retrospectively investigated from 2015 to 2021. Both univariate and multivariate logistic regression analyses were applied to evaluate independent risk factors for CRGNB-BSI. Results: The most common etiology was Klebsiella Pneumoniae (50.59%; 216/427), while the Acinetobacillus baumannii infection was associated with the highest mortality (58.25%) among all etiologies. The 60-day mortality of immunosuppressed patients with CRGNB-BSI was 52.48% (224/427). Procalcitonin (PCT) > 0.5 μg/L (OR = 2.32, 95% CI: 1.28– 4.19, P = 0.005) and age > 55 years (OR = 2.06, 95% CI: 1.17– 3.64, P = 0.012) were found to be predictors of 60-day mortality of CRGNB-BSI, and tigecycline regimen (OR = 3.20, 95% CI: 1.81– 5.67, P 0.5 μg/L, age > 55 years, and the tigecycline regimen were significantly associated with higher 60-day mortality among immunosuppressed patients with CRGNB- BSI. Patients developing MODS, septic shock, or AKI had worse clinical outcomes. Keywords: bloodstream infection, carbapenem-resistant, immunosuppressed patients, subgroups, prognosis Carbapenem-resistant Gram-negative bacteria (CRGNB) currently pose a great threat worldwide. Compared with other types of CRGNB infection, such as respiratory infection, urinary tract infection, and wound infection, CRGNB Bloodstream Infection has the highest mortality. 1,2 According to the China Antimicrobial Surveillance Network 2021 report, there were 301,917 bacterial samples in China in 2021, 14.4% of which came from blood, and the rate is rising each year. Moreover, there is an increasing trend in CRGNB. 3 Carbapenem-resistant Gram-negative bacteria bloodstream infections (CRGNB-BSI), including carbapenem-resistant Klebsiella pneumoniae (CRKP), Acinetobacter baumannii (CRAB), and Pseudomonas aeruginosa (CRPA), have emerged as a global public health problem with few effective treatments and are associated with high mortality. 4,5 Immunosuppressive status refers to low immune response or immunodeficiency. 6 Immunosuppressed patients having infections may present with atypical symptoms and worse prognosis. 7,8 They include patients receiving immunosuppressive therapy, such as oral immunosuppressive medications, chemotherapy, or radiotherapy; patients under transplantation states; patients with diseases such as diabetes, cancer, liver cirrhosis, and burns; and patients having a postoperative critical condition. 9,10 Previous studies explored certain specific immunosuppressed groups such as patients with cancers, transplantation status, hematological diseases, and diabetes, 5,11–13 but there is still a lack of research on CRGNB-BSI in the overall immunosuppressed population. In this retrospective study that aimed to determine the risk factors for CRGNB-BSI mortality in immunosuppressed patients, we explored the clinical characteristics, antibiotic strategies, microbiologi -Abstract Truncated-
pharmacology & pharmacy,infectious diseases